23 Feb Sangamo Therapeutics
Sandy Macrae, Ph.D., CEO
Oct. 13 | 2:00pm | AVROBIO Ballroom
Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance programs into the clinic. Our platforms have yielded multiple clinical-stage programs that could provide value in the near-to-mid-term. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality, and supply. Our ability to fund our projects enables us to execute and deliver on our mission.